Clinical assessment of repeated propofol-associated anesthesia in cats.
OBJECTIVE
To assess the effects of repeated episodes of propofol-associated anesthesia on quality of recovery from anesthesia, clinical status, and erythrocyte physiology in cats.


METHODS
Original study.


METHODS
37 cats undergoing short-duration anesthesia for radiotherapy.


METHODS
Twice daily on 5 consecutive days, 13 cats with squamous cell carcinoma of the nasal planum (group 1) underwent anesthesia: first via administration of propofol or a midazolam (0.2 mg/kg [0.09 mg/lb])-propofol combination and then via administration of ketamine and midazolam each day (latter data were not analyzed). During a 19-day period, 24 cats with vaccine associated sarcoma (group 2) were anesthetized 12 times with propofol or a midazolam-propofol combination. Anesthesia was maintained with propofol in both groups. Hematologic analysis was performed before, during, and on completion of radiotherapy; changes in Hct and hemoglobin concentration between groups were compared.


RESULTS
Mean duration of anesthesia was 8.1 minutes (range, 5 to 20 minutes); no adverse events were detected during recovery. Total dose of propofol administered did not differ between groups 1 (6.34 mg/kg [2.88 mg/lb]) and 2 (4.71 mg/kg [2.14 mg/lb]). Midazolam administration decreased the propofol dose by 26%. Overall decreases from baseline in Hct and hemoglobin concentration were not significantly different between the 2 groups, nor clinically important; however, compared with baseline, values in group 2 were significantly lower after 6 and 12 anesthetic episodes for both protocols. Heinz bodies were identified in low numbers in both groups during radiotherapy.


CONCLUSIONS
Results indicated that repeated propofol-associated short-duration anesthesia does not lead to clinically relevant hematologic changes in cats undergoing short-duration radiotherapy.
Bley
Carla Rohrer
CR
Section of Diagnostic Imaging and Radiation Oncology, Vetsuisse Faculty, University of Zurich, CH-8006 Zurich, Switzerland.
Roos
Malgorzata
M
Price
Jill
J
Ruess-Melzer
Katja
K
Buchholz
Julia
J
Poirier
Valerie
V
Kaser-Hotz
Barbara
B
D000771:Anesthesia, Intravenous / Q000009:adverse effects / Q000379:methods / Q000662:veterinary*; D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000662:veterinary; D002371:Cat Diseases / Q000532:radiotherapy; D002415:Cats / Q000097:blood / Q000502:physiology*; D004338:Drug Combinations; D005260:Female; D006366:Heinz Bodies; D006400:Hematocrit / Q000662:veterinary*; D006454:Hemoglobins / Q000032:analysis*; D007649:Ketamine / Q000008:administration & dosage; D008297:Male; D008874:Midazolam / Q000008:administration & dosage; D009669:Nose Neoplasms / Q000532:radiotherapy / Q000662:veterinary; D015742:Propofol / Q000008:administration & dosage* / Q000009:adverse effects; D012509:Sarcoma / Q000532:radiotherapy / Q000662:veterinary; D016896:Treatment Outcome; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary
D018686:Anesthetics, Intravenous; D004338:Drug Combinations; D006454:Hemoglobins; D007649:Ketamine; D008874:Midazolam; D015742:Propofol